Brivaracetam (ucb 34714)
P von Rosenstiel - Neurotherapeutics, 2007 - Elsevier
Brivaracetam (UCB 34714) is chemically related to levetiracetam (LEV, Keppra®). It
possesses a binding affinity for the synaptic vesicle protein 2A (SV2A) ten-fold above that of …
possesses a binding affinity for the synaptic vesicle protein 2A (SV2A) ten-fold above that of …
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
PA Calabresi, EW Radue, D Goodin, D Jeffery… - The Lancet …, 2014 - thelancet.com
Background Fingolimod has shown reductions in clinical and MRI disease activity in patients
with relapsing-remitting multiple sclerosis. We further assessed the efficacy and safety of …
with relapsing-remitting multiple sclerosis. We further assessed the efficacy and safety of …
[HTML][HTML] Oral orexin receptor 2 agonist in narcolepsy type 1
Y Dauvilliers, E Mignot, R del Río Villegas… - … England Journal of …, 2023 - Mass Medical Soc
Background Narcolepsy type 1 is caused by severe loss or lack of brain orexin
neuropeptides. Methods We conducted a phase 2, randomized, placebo-controlled trial of …
neuropeptides. Methods We conducted a phase 2, randomized, placebo-controlled trial of …
Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial
L Kappos, P O'Connor, EW Radue, C Polman… - Neurology, 2015 - AAN Enterprises
Objective: To assess long-term safety and efficacy of fingolimod in patients with relapsing-
remitting multiple sclerosis (RRMS). Methods: Patients completing FTY720 Research …
remitting multiple sclerosis (RRMS). Methods: Patients completing FTY720 Research …
Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study
Objective The 12-month (M), phase 3, double-blind, randomised TRANSFORMS study
demonstrated significant benefits of fingolimod 0.5 or 1.25 mg over interferon β-1a (IFNβ-1a) …
demonstrated significant benefits of fingolimod 0.5 or 1.25 mg over interferon β-1a (IFNβ-1a) …
Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis
Objective: To evaluate immune responses in fingolimod-treated patients with multiple
sclerosis (MS) against influenza vaccine (to test for responses against anticipated novel …
sclerosis (MS) against influenza vaccine (to test for responses against anticipated novel …
Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis
Objective: We investigated the determinants and clinical correlations of MRI-detected brain
volume loss (BVL) among patients with relapsing-remitting multiple sclerosis from the phase …
volume loss (BVL) among patients with relapsing-remitting multiple sclerosis from the phase …
Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial‐onset seizures: a phase IIb, randomized, controlled trial
W Van Paesschen, E Hirsch, M Johnson, U Falter… - …, 2013 - Wiley Online Library
Purpose: To evaluate the efficacy and tolerability of adjunctive brivaracetam (BRV), a novel
high‐affinity synaptic vesicle protein 2A ligand that also displays inhibitory activity at …
high‐affinity synaptic vesicle protein 2A ligand that also displays inhibitory activity at …
Switching from natalizumab to fingolimod: a randomized, placebo-controlled study in RRMS
L Kappos, EW Radue, G Comi, X Montalban… - Neurology, 2015 - AAN Enterprises
Objective: To investigate the effect of different natalizumab washout (WO) periods on
recurrence of MRI and clinical disease activity in patients switching from natalizumab to …
recurrence of MRI and clinical disease activity in patients switching from natalizumab to …
Fingolimod in relapsing multiple sclerosis: an integrated analysis of safety findings
Background Fingolimod 0.5 mg once daily is the first approved oral therapy for relapsing
multiple sclerosis (MS). Objective To report integrated long-term safety data from phase 2/3 …
multiple sclerosis (MS). Objective To report integrated long-term safety data from phase 2/3 …